NUCLEIC ACID SEQUENCING METHOD AND APPARATUS
20230265498 · 2023-08-24
Inventors
- Yaozhong ZOU (Chengdu, Sichuan, CN)
- Yunpeng SU (Chengdu, Sichuan, CN)
- Ronghuo QIN (Chengdu, Sichuan, CN)
- Peng JIANG (Chengdu, Sichuan, CN)
- Jiazhi LIU (Chengdu, Sichuan, CN)
Cpc classification
C12Q2525/101
CHEMISTRY; METALLURGY
C12Q2537/157
CHEMISTRY; METALLURGY
C12Q2563/116
CHEMISTRY; METALLURGY
C12Q2525/101
CHEMISTRY; METALLURGY
C12Q2563/116
CHEMISTRY; METALLURGY
C12Q1/6806
CHEMISTRY; METALLURGY
International classification
Abstract
A method for determining the type of a nucleotide on a nucleic acid sequence to be analyzed, and a nucleic acid sequencing method. In the method, at least one modified nucleotide for nucleic acid synthesis is separated from a nucleic acid sequence to be analyzed and other components on both sides of a membrane; when the modified nucleotide is transferred to the other side of the membrane under the action of an electric field by means of a nanopore embedded on the membrane, a synthesis reaction is conducted; moreover, the type of a base of the nucleotide is determined according to the change of the electrical properties of the nanopore in the process of the modified nucleotide is transferred by the nanopore, so as to implement sequencing.
Claims
1. A method for determining type of a nucleotide on a nucleic acid sequence to be analyzed, comprising the steps of: S01 providing at least one nucleotide molecule in a first compartment and a nucleic acid sequence to be analyzed in a second compartment, with the first compartment and the second compartment separated by a membrane having at least one nanopore; S02 applying an electric field to drive the nucleotide molecule and/or a part thereof to pass through the nanopore in a first direction or to be inserted in the nanopore; S03 measuring a first current characteristic value passing through the membrane in the state of S02 to identify the nucleotide molecule and/or a part thereof; S04 applying an electric field in a direction opposite to that of the electric field applied in step S02 or in the same direction but with a lower driving voltage, causing the nucleotide molecule and/or a part thereof to pass through the nanopore and/or exit the nanopore in a second direction, with the second direction being opposite to the first direction; S05 measuring a second current characteristic value passing through the membrane to identify the nucleotide molecule and/or a part thereof, comparing the second current characteristic value with a pre-determined standard current characteristic value of the nucleotide molecule or polyphosphate molecule in the state of S04 to determine whether the nucleotide molecule and/or a part thereof is attached to the nucleic acid sequence to be analyzed, and thus determining the type of nucleotide on the nucleic acid sequence to be analyzed in the second compartment.
2. The method according to claim 1, wherein the nucleotide molecule is a modified nucleotide molecule as shown in Formula I.
NXP-L-B Formula I wherein NXP represents a phosphate deoxyribonucleotide and/or a phosphate nucleotide, the phosphate deoxyribonucleotides comprising dAXP, dTXP, dCXP and dGXP; the phosphate nucleotides comprising AXP, TXP/UXP, CXP and GXP. L represents a linker part having a long chain segment and a linking segment. B represents a bulky steric hindrance part, which is a protein molecule, and is connected to the linker part through the linking segment.
3. The method according to claim 1, wherein the membrane is selected from a natural lipid bilayer or a bilayer membrane formed by artificial amphiphilic molecules.
4. The method according to claim 1, wherein the nanopore is selected from a natural protein nanopore or a nanopore prepared from artificial material.
5. The method according to claim 1, wherein a nucleic acid polymerase and a template primer are further provided in the second compartment.
6. A sequencing method for a nucleic acid sequence to be analyzed, comprising repeating steps S01 to S05 of the method according to claim 1, sequentially determining type of each nucleotide of the nucleic acid sequence to be analyzed until the sequencing of the nucleic acid sequence to be analyzed is completed.
7. A nucleic acid sequencing device for the method according to claim 1, comprising: (a) a first compartment and a second compartment separated by a membrane having at least one nanopore; (b) means for applying an electric field across the membrane; and (c) components used to measure a current flowing through the membrane.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
DETAILED DESCRIPTION OF THE INVENTION
[0033] It should be understood that the different applications of the methods disclosed herein may vary according to the specific needs of the art. It should also be understood that the terms used herein are intended to describe specific embodiments of the invention only and are not intended to be limiting.
[0034] The present invention provides a method for determining the type of nucleotide on a nucleic acid sequence using a nanopore on a bilayer membrane and modified nucleotides. The present invention also provides a sequencing method for a nucleic acid sequence using a nanopore on a bilayer membrane and modified nucleotides. The modified nucleotides are complexes as shown in Formula I:
NXP-L-B Formula I [0035] wherein NXP (Nucleoside phosphate) represents a phosphate deoxyribonucleotide and/or a phosphate nucleotide, the phosphate deoxyribonucleotides comprising dAXP, dTXP, dCXP and dGXP; the phosphate nucleotides comprising AXP, TXP/UXP, CXP and GXP.
[0036] As used herein, the term “phosphate deoxynucleotide” includes, but is not limited to, monophosphate deoxynucleotides and polyphosphate deoxynucleotides, wherein polyphosphate deoxynucleotides include, but are not limited to, diphosphate deoxynucleotides, triphosphate deoxynucleotides, tetraphosphate deoxynucleotides, pentaphosphate deoxynucleotides and hexaphosphate deoxynucleotides, preferably triphosphate deoxynucleotides. For the purposes of the present invention, the term “phosphonucleotide” includes, but is not limited to, monophosphate nucleotides and polyphosphate nucleotides, wherein polyphosphate nucleotides include, but are not limited to, diphosphate nucleotides, triphosphate nucleotides, tetraphosphate nucleotides, penta-phosphate nucleotides and hexaphosphate nucleotides, preferably triphosphate nucleotides.
[0037] The phosphoribonucleotides and/or phosphodeoxynucleotides employed in the present invention can also be modified at multiple sites, such as, but not limited to, the second position on ribose, the fifth position on pyrimidines, and the seventh position on purines. Any manner of modification, as long as the modified phosphate nucleotide and/or phosphate deoxynucleotide can still support efficient nucleic acid synthesis reactions, can be a candidate modification option in the present invention to help obtain better sequencing results. According to their corresponding blocking currents, appropriate modifications can be screened to make the characteristic blocking currents of different nucleotides more distinguishable and the signals clearer and easier to be identified. In addition to this, modifications can also alter the size, or charge characteristics, of phosphonucleotide and/or phosphodeoxynucleotide molecules, thereby slowing their entry, transit and/or exit times into the nanopore, helping to obtain clearer and more accurate current measurements.
[0038] In the method of the present invention, the nucleic acid sequence to be analyzed may be a DNA nucleic acid sequence or an RNA nucleic acid sequence. When determining the type of nucleotide in a DNA nucleic acid sequence or sequencing a DNA nucleic acid sequence, either DNA polymerase can be used to employ modified deoxyribonucleotides (dATP, dTTP, dCTP, and dGTP) or RNA polymerase can be used to synthesize an RNA strand using a DNA template and modified nucleotides (ATP, TTP/UTP, CTP, and GTP). When determining the nucleotide type in the RNA nucleic acid sequence or sequencing the RNA nucleic acid sequence, reverse transcriptase can be used to synthesize a cDNA strand complementary to it using the above-mentioned deoxyribonucleotides as a template.
[0039] L represents a linker part having a long chain segment and a linking segment.
[0040] The long chain segment is preferably a biocompatible straight chain polymer.
[0041] Biocompatible straight chain polymers that can be used in the present invention include, but are not limited to, straight chain polypeptides, preferably straight chain polypeptides. As the main structure of the long chain segment itself, in addition to straight chain polypeptides, other chemical chain polymers such as polymers formed by phosphodiester bonds (similar to the main chain structure of nucleic acids), polyethylene glycol PEG, and suitable nanowires, etc., can also be used in the present invention. The length range of the long chain segment can be adjusted according to the scale of the nanopore protein chosen and the different ways of coupling the nanopore and the nucleic acid polymerase. In the present invention, the long chain segments may have a length range in the range of 5 to 25 nm, preferably in the range of 8 to 15 nm.
[0042] In the present invention, different linkers can be distinguished by subscript letters, such as L.sub.N, L.sub.A, L.sub.T, L.sub.U, L.sub.C, L.sub.G, etc., where the subscripts A, T, U, C and G represent the type of nucleotide linked to the linker part L, and N is a generic representation of the nucleotide, which can be any one of A, T, U, C and G.
[0043] The linking segment that can be used in the present invention is for example, but not limited to, biotin, maleimide, etc. The linking segment has the ability to bind specifically to a specific protein, for example biotin binds specifically to biotin-binding protein.
[0044] B represents a bulky steric hindrance part, and as used herein, the term “bulky steric hindrance part” refers to a biomolecular part having a diameter greater than 1 to 2 nm, preferably greater than 2 nm, and more preferably greater than 3 nm. The bulky steric hindrance part is selected from a protein molecule, preferably a globular protein molecule. The bulky steric hindrance part is characterized by a structurally stable nature and is linked to the linker part by the above-mentioned linking segment, such as, but not limited to, a biotin-binding protein, which is linked to the linker by biotin. In addition to the use of biotin/biotin-binding protein to couple proteins at the end of the linker chain, the use of other proteins or other blockers with diameters larger than the nanopore, and other coupling methods are also applicable to the present invention. For example, a maleimide active group is added to the end of the linker by chemical synthesis as a linking segment, and then any stable, spherical protein with a size larger than the nanopore pore size is selected. For example, in some preferred embodiments, xylanase is employed as the bulky steric hindrance part, and cysteine is introduced at the C-terminus of the recombinant protein, which is covalently coupled to the linking segment maleimide using its sulfhydryl group —SH.
[0045] After said modified nucleotide molecule passes through the nanopore or is inserted in the nanopore, said linker allows the phosphonucleotide part to be confined near the opening of the nanopore. In addition, the linker assists in controlling the reverse passage time of the phosphonucleotide or phosphate group through the nanopore. The linker can be chemically modified to introduce charged groups, such as —NH.sub.2 group carrying a positive charge or —PO.sub.4 group carrying a negative charge in the system's operating pH range (6-9). The variation of the charge density and charge sites introduced on the chain allows the entire modified nucleotide molecule, i.e., the phosphonucleotide/phosphate deoxynucleotide-linker-bulky steric hindrance molecule complex, to be subjected to different driving forces in the electric field, thus affecting the timing and manner of interaction of the nucleotide part with the nanopore, as well as the direction of motion at a given voltage. For example, introducing a positive charge near the site where the linker is attached to the phosphate nucleotide reduces the net negative charge density of the complex, allowing the nucleotide to be driven by a reduced electric field in the nanopore, thus allowing it to exit the nanopore in the second direction even at high voltages, facilitating the recording of the current characteristics at high voltages when exiting the nanopore and improving the signal-to-noise ratio.
[0046] As used herein, the term “lipid bilayer” refers to a membrane prepared based on the tendency of lipid molecules, such as but not limited to phospholipids, to form stable lipid bilayers in the aqueous phase. The lipid bilayer that may be used in the present invention includes, but is not limited to phospholipid bilayers.
[0047] As used herein, the term “nanopore” refers to a nano-sized pore which can be formed by pores in porous proteins or synthetic materials such as silicon or graphene. Protein pores in electrically insulating membranes or artificial solid pores machined from insulating materials can be used as single molecule detectors. It can be a bioprotein channel in a highly resistive lipid bilayer, a protein channel in a synthetic membrane or directly an artificial solid state pore. Two general approaches exist for the preparation of nanopores for nucleic acid analysis: (1) Organic nanopores prepared from naturally occurring molecules, such as α-hemolysin pores. (2) Synthetic solid-state nanopores generated by several conventional and unconventional fabrication techniques.
[0048] As used herein, the terms “nucleotide” and “NXP” cover both nucleotides and deoxyribonucleotides, unless the context specifically indicates otherwise.
[0049] In some embodiments, the sequencing system of the present invention involves the formation of a phospholipid bilayer for separating and insulating the cis and trans sides of the bilayer and providing a suitable chemical environment for the nanopore to embed, forming a small pore of 1.4 to 2 nm diameter to pass through the cis and trans sides, thereby allowing ions to pass through to form microcurrents under the action of an electric field. Using, for example, but not limited to, the phospholipid 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DPhPC) or other amphiphilic compounds, there are currently a variety of available methods, such as coating, folding, microfluidic methods, etc., for forming phospholipid bilayers on scales of several microns to 200 microns across surface materials with hydrophobic properties, such as polyimide, polyethylene, etc. These methods have been reported in numerous literature sources describing the materials and steps for their specific implementation, and will not be repeated in the present invention.
[0050] The present invention is quite adaptable and can theoretically employ a variety of different transmembrane nanopores for the transport and recognition of phosphonucleotides, such as but not limited to α-hemolysin, γ-hemolysin, MspA, OmpF, etc. Nanopores can be used for sequencing in the manner described herein as long as they are structurally stable after being embedded in phospholipid membranes, the corresponding currents are relatively stable and measurable, and the pore size is appropriate to allow the passage of phosphonucleotides and linkers while blocking large-sized proteins. In addition to wild-type nanopore proteins, the present invention can also employ modified variants of nanopore proteins. Finally, in addition to protein nanopores, the present invention is equally applicable to artificial solid-state nanopores as long as they meet the prerequisites of current stability and appropriate pore size.
[0051] By applying a voltage of, for example, 50-300 mV, such as 75 mV-275 mV, 100 mV-250 mV, 125 mV-225 mV, 150 mV-200 mV, or 80 mV, 90 mV, 100 mV, 125 mV, 150 mV, 175 mV, 180 mV, 190 mV, 200 mV, or any value between any of the above voltage values, to both sides of the insulating lipid bilayer, the system will form a potential gradient across the membrane along the inner diameter of the nanopore. The electrolyte is driven by the potential gradient to form a current in the nanopore by directed motion within the nanopore, i.e., the open nanopore current. When the negatively charged nucleotide part approaches the nanopore opening under the dual action of free diffusion and electrophoretic motion, it will be captured by the potential gradient along the nanopore and thus driven by the electric field force through the narrow nanopore to achieve transmembrane transport. In this process, the nucleotides will interfere to some extent with the movement of the electrolyte in the nanopore, thus changing the current magnitude and creating a so-called blocking current. The four different bases A, T(U), C, and G of different nucleotides can be distinguished from each other by the blocking currents formed by their interaction with nanopores due to differences in structure and physicochemical properties, as well as in linker structure. Recording and identifying this characteristic blocking current can be used to determine the type of nucleotide bases passing through the nanopore.
[0052] In the method of the present invention, the modified nucleotide part connected to the linker passes through the nanopore under the action of a strong electric field, but the bulky steric hindrance part connected to the linker cannot pass through the nanopore due to its size and therefore remains on one side of the nanopore while the linker part is located in the nanopore. When the applied voltage is reduced and the electric field effect is weakened, the nucleotide or its enzymatically reacted pyrophosphate part will exit the nanopore in the second direction described above. During exit, the intact nucleotide and pyrophosphate will give distinguishable current characteristics to help determine whether the exit group on the linker is the intact nucleotide or the enzymatically reacted product pyrophosphate. By recording the different characteristic currents flowing through the nanopore, the method of the present invention can accurately identify the type of nucleotide passing through the nanopore and determine whether the nucleotide is captured by nucleic acid polymerase and involved in nucleic acid synthesis. The method records the current values in the fully open state of the nanopore; the current characteristic values of nucleotides (both nucleotides and deoxynucleotides) interacting with linker and nanopore at a high voltage, for example, not less than 160 mV, not less than 170 mV, not less than 180 mV, not less than 190 mV, not less than 200 mV; and the current characteristics values of linker carrying the nucleotide/or pyrophosphate exiting the nanopore in the second direction at a low voltage, for example, not higher than 100 mV, not higher than 90 mV, not higher than 80 mV, not higher than 70 mV, not higher than 60 mV, not higher than 50 mV.
[0053] The type of nucleotide passing through the nanopore and whether it successfully participates in nucleic acid synthesis is deduced through the logical relationship of the above-mentioned current value with time and system state. The method has great potential and value in reducing deletion errors and insertion errors in nucleic acid sequencing using a nanopore, thereby improving sequencing accuracy.
[0054] The electrolyte solution used in the present invention is an electrolyte solution suitable for performing nucleic acid synthesis, such as a KCl solution, specifically a KCl solution with a concentration of 0.1 to 1 M, such as 0.3M KCl solution, 0.5M KCl solution. Under the pH conditions of the electrolyte solution of the present invention, the nucleotide part of the complex of the present invention is negatively charged and can reach the trans side (the second compartment) from the cis side of the phospholipid membrane (the first compartment) through the nanopore along the potential gradient in the electric field. When the nucleotide part reaches the trans side, it can be captured and utilized by the nucleic acid polymerase coupled to the nanopore through free diffusion. And the nucleotide part may interact with the nanopore as it enters/passes through the nanopore thereby generating a characteristic blocking current and is recorded by a microcurrent measurement system connected to the nanopore, thereby determining the base type of this nucleotide being transported by the nanopore.
[0055] The present invention provides a way to allow the phosphonucleotide part (or pyrophosphate part, if the synthesis reaction has been carried out) that has passed through the nanopore to the trans side of the phospholipid membrane to return to the cis side through the nanopore again and thus be detected by the nanopore a second time. In some embodiments of the present invention, the nucleotide phosphates are linked by PEG or similar long chains, and a biotin/biotin-binding protein complex. Due to the size much larger than the nanopore aperture, the biotin/biotin-binding protein complex cannot pass through the nanopore but remains on the cis side and confines the nucleotide part near the opening on the trans side of the nanopore by the PEG-linking chain spanning the nanopore. When the electric field force is weakened, the nucleotide near the opening on the trans side of this nanopore will pass through the nanopore again under thermal movement or diffusion and return to the cis side and generate the characteristic blocking current for the second time. Depending on whether the second characteristic blocking current corresponds to an intact nucleotide or to pyrophosphate after the synthesis reaction is complete, it can be used to determine whether this nucleotide is involved in the nucleic acid synthesis reaction.
[0056] The present invention relates to a way of covalently coupling a nucleic acid polymerase to a nanopore on the trans side, thereby helping to limit the distance between the polymerase active center and the opening on the trans side of the nanopore to the range of 1 to 3 nm. After the phosphate nucleotide enters the trans side through the nanopore, the phosphate nucleotide is also confined nearby by the long chain of linker, which corresponds to a great increase in the effective local concentration of polymerase and nucleotide, thus greatly reducing the time for the phosphate nucleotide to be captured by the polymerase and contributing to the sequencing efficiency of the present invention.
[0057] In addition to using the characteristic blocking current to determine the base type of the nucleotide being transported by the nanopore, the present invention also allows inferring whether the transported nucleotide is involved in DNA synthesis. As mentioned earlier, phosphonucleotides that are transported to the trans side by the nanopore are confined near the nanopore opening by the long chain of linker. After a certain time, the nucleotide (or pyrophosphate if the nucleotide participates and completes the nucleic acid synthesis reaction) eventually passes back to the cis side through the nanopore again by diffusion, regardless of whether it participates in the synthesis reaction or not. If this nucleotide is not involved in the synthesis reaction, then the system will again record the characteristic blocking current corresponding to the exit of the intact nucleotide from the nanopore; conversely, the system will detect the blocking current caused by the exit of pyrophosphate from the nanopore.
[0058] In summary, the present invention is implemented so that each nucleotide involved in a nucleic acid synthesis reaction must be transported through the nanopore and its characteristic blocking current is recorded, so as to obtain the information of its base type. After a certain period of time, the molecules transported or entering the trans side pass through the nanopore again and are transported back to the cis side, and in this process, it is determined whether the nucleotide participates in the synthesis reaction. By monitoring each nucleotide that may come into contact with the polymerase and inferring whether it is involved in the reaction, the present invention can obtain the sequence of the template DNA (or RNA) to be analyzed and effectively avoid deletion errors and insertion errors during the sequencing process, obtaining an increase in accuracy.
[0059] The present invention is further illustrated by the following examples, which should not be construed as limiting.
EXAMPLES
Example 1 Design and Preparation of the Complex of Nucleotide-Linker-Bulky Steric Hindrance Part
[0060] In this example, the linker part was chosen to use a long chain polypeptide. One end of the polypeptide was attached to the third phosphate group of the deoxynucleotide triphosphate dNTP and the other end was attached to the maleimide. Different nucleotides of A, T, C and G were attached to different sequences of the polypeptide to facilitate the determination of the base type based on different characteristic blocking current values.
[0061] The bulk steric hindrance protein part was the globular protein xylanase, which is structurally stable. The nucleotide-linker-bulky steric hindrance part complex was synthetically prepared by introducing a cysteine residue at the C-terminus of xylanase through protein recombination, and its sulfhydryl-SH formed a stable covalent bond with the maleimide of the linker part.
Example 2 Preparation of Phospholipid Bilayer with Nanopore
[0062] The compartment system that meets the requirements of the present invention was purchased from Warner Instruments, and the aperture size between the left and right compartments was chosen to be 150 μm. The hydrophobic material near the opening was suitable for phospholipid adhesion. A 0.3 M solution of KCl was added to each of the left and right small compartments with the liquid level below the opening. 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DphPC) was selected and dissolved in the organic solvent pentane at a final concentration of 10 mg/ml. This phospholipid solution was added to the existing KCl solution in the compartment to form an organic phase that covered the KCl liquid surface. By adding 0.3 M KCl solution along the outer wall of the compartment, the organic phase containing the phospholipid layer rose with the liquid level thereby flooding the small pore between the two compartments. During this process phospholipids bound to hydrophobic materials near the pore and spontaneously formed a phospholipid bilayer across the pore.
[0063] The nanopore solution was added to the first compartment to a final concentration of 1 nM, while testing the current between the two compartments. When a single-molecule nanopore was spontaneously inserted into the phospholipid bilayer, the system would detect the nanopore opening current. The excess nanopore solution was removed in time to ensure that only a single-molecule nanopore channel was present in the phospholipid membrane.
[0064] Cysteine was introduced at the trans side of the above nanopore. After the nanopore was successfully embedded in the phospholipid membrane, it was coupled together with DNA polymerase which also carried cysteine, using maleimide-PEG-maleimide (available from the reagent company nanosoft polymers) as a linkage intermediary. The coupled polymerase as well as the corresponding DNA template to be analyzed and primer components were in the second compartment.
[0065] The phospholipid membrane with nanopore and DNA replication components (without nucleotides) were prepared by the above operation.
Example 3 Determination of Standard Current Characteristic Value and Acquisition of Standard Current Characteristic Profile
[0066] The nucleic acid sequencing device as described in
[0067] A 5 μM concentration of dATP-L.sub.A-B complex prepared as described in Example 1 was added to the first compartment at a voltage value of 180 mV, while the change in current value through the nanopore was recorded at a sampling frequency of 1 KHz or more. In this process, the system first recorded the open nanopore I.sub.o, and then the dATP part passed through the nanopore under the electric field from the first compartment into the second compartment, and remained relatively stable under the electric field driving force. At this point the system recorded the current I.sub.A1 formed by the dATP-L.sub.A-B complex in interaction with the nanopore; after 400 ms the voltage value was reduced to 80 mV and continued for 200 ms to record the characteristic current profile I.sub.A2 caused by the exit of dATP from the nanopore in the direction from the second compartment to the first compartment. The above voltage stimulation protocol was repeatedly used to continuously record current changes for 15 minutes to obtain a sufficiently large sample size to obtain a range of characteristic blocking current values I.sub.A1 for dATP-L.sub.A-B at 180 mV, as well as to clarify the reproducibility of the characteristics presented by the current profile I.sub.A2.
[0068] The ranges of the respective values of the standard current characteristic values I.sub.T1, I.sub.C1, and I.sub.G1 corresponding to dTTP, dCTP, and dGTP were determined in the same way, and the characteristic current profiles I.sub.T2, I.sub.C2, and I.sub.G2 when the corresponding nucleotides exited the nanopore were recorded, respectively.
[0069] The characteristic current profiles I.sub.A3, I.sub.B3, I.sub.C3 and I.sub.G3 of the four complexes, PP-L.sub.A-B, PP-L.sub.T-B, PP-L.sub.C-B and PP-L.sub.G-B, during the exit of the PP part from the second compartment back to the first compartment at 80 mV were recorded in the above manner.
Example 4 Determination of Nucleic Acid Sequence
[0070] The nucleic acid sequence to be analyzed was synthesized by Tsingke Biotechnology Co., Ltd., Beijing, as described in SEQ ID NO. 1,
TABLE-US-00001 SEQ ID NO. 1: S′ ATAGACGCGGCCAAATTACGGCCGAT 3′ [0071] where the underlined part is the complementary sequence of the binding primer.
[0072] Primer sequence is as described in SEQ ID NO. 2.
TABLE-US-00002 SEQ ID NO. 2: 5′ ATCGGCCGTAATTTGGCC 3′
[0073] In the sequencing device as shown in
[0074] The nucleotide complexes prepared as described in Example 1 were dissolved in a 0.3 M KCl solution and added to the first compartment of the nucleic acid sequencing device.
[0075] First Cycle: [0076] applying a positive electric field V.sub.1=180 mV directed from the first compartment to the second compartment for a duration t.sub.1=400 ms and recording the current change, [0077] applying a positive electric field V.sub.2=80 mV directed from the first compartment to the second compartment for a duration t.sub.2=200 ms, and recording the current change, [0078] applying a reverse electric field V.sub.3=−180 mV directed from the second compartment to the first compartment for a duration t.sub.3=5 ms to ensure that all macromolecules exitted the nanopore completely;
[0079] Second Cycle:
[0080] . . .
[0081] Until end of sequencing.
[0082] Based on the current variation graphs obtained for each cycle described above, the measured current values were compared to the individual standard current characteristic values measured in Example 3 to determine the type of nucleotide that crossed the nanopore in each cycle, as well as to determine whether the nucleotide was successfully synthesized onto the nucleic acid sequence to be analyzed.
[0083] Based on the above analysis and judgment, it was determined that the nucleotides involved in the synthesis reaction were GCGTCTAT in order, so the original nucleic acid sequence to be analyzed was ATAGACGC from 5′ to 3′.
[0084] The present invention is not limited to the particular embodiments described in this application, which are intended as a single illustration of various aspects of the present invention. Many modifications and variations of the invention can be made without departing from the spirit and scope of the invention, as will be apparent to those skilled in the art. Functionally equivalent methods and apparatuses within the scope of the present invention, other than those enumerated herein, will become apparent to those skilled in the art from the foregoing description. These modifications and variations are intended to fall within the scope of the appended claims. The invention is limited only by the terms of the appended claims and the full scope of the equivalents of those claims. It should be understood that the present invention is not limited to particular methods, reagents, compound compositions, or biological systems that are of course subject to variation. It should also be understood that the terms used herein are intended to describe particular embodiments only and are not limiting.